Novartis: Hypersensitivity trials
The registry lists 13 Hypersensitivity studies with Novartis as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 8Phase 2 4Phase 3 2Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in JapanCompletedNCT06240741Phase 3Results posted
- Systemic Corticosteroids Avoidance Study in Severe Asthma PatientsTerminatedNCT03629249Phase 3Results posted
- Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart FailureCompletedNCT01982292Phase 2Results posted
- Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With AsthmaCompletedNCT01716754Phase 2Results posted
- Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonistsCompletedNCT00670930Phase 4Results posted
- A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic AsthmaCompletedNCT01703312Phase 1/2
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male SubjectsCompletedNCT01596712Phase 1
- To Demonstrate the Relative Bioavailability Study of Promethazine HCl 50 mg Tablets Under Fasting ConditionsCompletedNCT00947063Phase 1
- To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg TabletsCompletedNCT00946608Phase 1
- To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg TabletsCompletedNCT00913549Phase 1
- To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed ConditionsCompletedNCT00881634Phase 1
- To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting ConditionsCompletedNCT00881127Phase 1
- Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass PollenCompletedNCT00426179Phase 1/2